Tonix's TONMYA launch is tracking well ahead of prior expectations, with Q2 net sales nearly tripling QoQ and meaningful payer coverage milestones achieved ($136M lives, 43% coverage). The coming sales force expansion to ~150 reps and managed Medicare access in Jan 2027 support continued prescription growth. Monitor the cadence of bridge-to-revenue conversions, cash burn trajectory, and Phase 2 HORIZON MDD study enrollment as the next catalysts.
Price Chart
Executive Summary
Tonix Pharmaceuticals reported Q2 2026 net product revenue of $13.5M, up 578% YoY from $2.0M, driven by $11.0M in TONMYA net sales (up 197% QoQ). Commercial payer access expanded to ~136M covered lives (43% of U.S.). Net loss widened to $40.6M (-$2.44/sh) on higher SG&A and R&D, vs -$28.3M (-$3.86/sh) a year ago. At $176.2M cash, runway extends into early Q2 2027. The TONMYA launch trajectory is the key catalyst for equity value.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue $13.5M vs $2.0M YoY (up 578%); TONMYA net sales alone $11.0M, up 197% QoQ from Q1
- Total prescriptions rose 100% QoQ to 12,592; refills up 207% QoQ; new patient scripts up 36% QoQ
- Commercial payer coverage expanded to ~136M covered lives (43% of U.S.); Medicare coverage agreement adds ~9M lives Jan 1, 2027
- Sales force to expand by 50 reps to ~150 by September 2026
- Net loss $40.6M (-$2.44/sh) vs $28.3M (-$3.86/sh) YoY; weighted shares up 127% YoY to 16.6M
- Cash $176.2M at June 30, 2026; raised $3.7M post-quarter via ATM; runway into early Q2 2027
Financial Impact
Total revenue $13.5M (578% YoY); TONMYA net sales $11.0M, up 197% QoQ; cash burn $84.6M in H1 2026 operating cash flow vs $31.4M H1 2025
Risk Factors
- Bridge prescriptions do not immediately generate net product revenue; conversion risk remains
- Cash burn accelerated to $84.6M operating cash outflow in H1 2026 vs $31.4M in H1 2025; reliance on ATM facility
- Dilution risk: weighted share count 16.6M at Q2 end, up 127% YoY; additional ATM sales post-quarter
- Launch of a first-in-class fibromyalgia drug requires sustained prescriber adoption and payer reimbursement expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036740 |
| Document: form8-k.htm | 0001493152-26-036740 |
| Document: 0001493152-26-036740-index-headers.html | 0001493152-26-036740 |
| Document: 0001493152-26-036740-index.html | 0001493152-26-036740 |
| Document: 0001493152-26-036740.txt | 0001493152-26-036740 |
| 8-K Data (Synthetic) | 0001493152-26-036740 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers